- Home
- MIRA vs LRE Comparison
MIRA vs LRE Comparison
Compare MIRA & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- LRE
- Stock Information
- Founded
- MIRA 2020
- LRE 2001
- Country
- MIRA United States
- LRE Japan
- Employees
- MIRA N/A
- LRE N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- LRE
- Sector
- MIRA Health Care
- LRE
- Exchange
- MIRA Nasdaq
- LRE Nasdaq
- Market Cap
- MIRA 19.7M
- LRE 17.6M
- IPO Year
- MIRA 2023
- LRE 2023
- Fundamental
- Price
- MIRA $1.33
- LRE $1.20
- Analyst Decision
- MIRA Strong Buy
- LRE
- Analyst Count
- MIRA 2
- LRE 0
- Target Price
- MIRA $14.00
- LRE N/A
- AVG Volume (30 Days)
- MIRA 3.4M
- LRE 10.4K
- Earning Date
- MIRA 05-27-2025
- LRE 01-01-0001
- Dividend Yield
- MIRA N/A
- LRE N/A
- EPS Growth
- MIRA N/A
- LRE N/A
- EPS
- MIRA N/A
- LRE 0.29
- Revenue
- MIRA N/A
- LRE $117,804,154.00
- Revenue This Year
- MIRA N/A
- LRE N/A
- Revenue Next Year
- MIRA N/A
- LRE N/A
- P/E Ratio
- MIRA N/A
- LRE $4.10
- Revenue Growth
- MIRA N/A
- LRE 8.82
- 52 Week Low
- MIRA $0.51
- LRE $1.10
- 52 Week High
- MIRA $5.01
- LRE $13.76
- Technical
- Relative Strength Index (RSI)
- MIRA 67.19
- LRE 46.94
- Support Level
- MIRA $1.03
- LRE $1.22
- Resistance Level
- MIRA $1.30
- LRE $1.29
- Average True Range (ATR)
- MIRA 0.11
- LRE 0.12
- MACD
- MIRA 0.02
- LRE -0.01
- Stochastic Oscillator
- MIRA 97.44
- LRE 12.20
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.